Nanomolar-potency small molecule inhibitor of STAT5 protein

ACS Medicinal Chemistry Letters

Volumn 5, Issue 11, 2014, Pages 1202-1206

  Cumaraswamy, Abbarna A ^a   Lewis, Andrew M ^a   Geletu, Mulu ^a   Todic, Aleksandra ^a   Diaz, Diego B ^a   Cheng, Xin Ran ^a   Brown, Carla E ^a   Laister, Rob C ^c   Muench, David ^b   Kerman, Kagan ^a   Grimes, H Leighton ^b   Minden, Mark D ^c   Gunning, Patrick T ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

anticancer drug; leukemia cells; protein protein interactions; small molecule inhibitor; STAT5

Indexed keywords

PROTEIN INHIBITOR; STAT3 PROTEIN; STAT5 PROTEIN;

ARTICLE; COMPLEX FORMATION; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION;

EID: 84926465672     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500165r     Document Type: Article

References (22)

1. Hasinoff, B. B.; Patel, D. The lack of target specificity of small molecule anticancer kinase inhibitors correlated with their ability to damage myocytes in vitro Toxicol. Appl. Pharmacol. 2010, 249, 132-39
2. Mouhayar, E.; Durand, J. B.; Cortes, J. Cardiovascular toxicity of tyrosine kinase inhibitors Expert. Opin. Drug Saf. 2013, 12, 687-96
3. Yang, B.; Papoian, T. Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome J. Appl. Toxicol. 2012, 32, 945-51
4. Engelman, J. A.; Settleman, J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy Curr. Opin. Genet. Dev. 2008, 18, 73-79
5. Barouch-Bentov, R. Mechanisms of drug-resistance in kinases Expert Opin. Invest. Drug 2011, 2, 153-208
6. Daub, H.; Specht, K.; Ullrich, A. Strategies to overcome resistance to targeted protein kinase inhibitors Nat. Rev. Drug. Discovery 2004, 3, 1001-10
7. Shyh-Han, T.; Nevaleinen, M. T. Signal transducer and activator of transcription 5A/B in prostate and breast cancers Endocr. Relat. Cancer 2008, 15, 367-90
8. Becker, S.; Groner, B.; Muller, C. W. Three-dimensional structure of the Stat3beta homodimer bound to DNA Nature 1998, 394, 145-51
9. Chen, X.; Vinkemeier, U.; Zhao, Y.; Jeruzalmi, D.; Darnell, J. E.; Kuriyan, J. Crystal structure of a tyrosine phosphorylated Stat-1 dimer bound to DNA Cell 1998, 93, 827-39
10. Nosaka, T.; Kawashima, T.; Misawa, K.; Ikuta, K.; Mui, A. L.; Kitamura, T. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells EMBO J. 1999, 18, 4754-65
11. Cumaraswamy, A. A.; Todic, A.; Resetca, D.; Minden, M. D.; Gunning, P. T. Inhibitors of Stat5 protein signaling MedChemComm 2012, 3, 22-27
12. Muller, J.; Sperl, B.; Reindl, W.; Kiessling, A.; Berg, T. Discovery of chromone-based inhibitors of the transcription factor Stat5 ChemBioChem 2008, 9, 723-27
13. Nelson, E. A.; Walker, S. R.; Xiang, M.; Weisberg, E.; Bar-Natan, M.; Barrett, R.; Liu, S.; Kharbanda, S.; Christie, A. L.; Nicolais, M.; Griffin, J. D.; Stone, R. M.; Kung, A. L.; Frank, D. A. The STAT5 inhibitor pimozide displays efficacy in models of acute myelogenous leukemia driven by FLT3 mutations Blood 2011, 117, 3421-29
14. Walker, S. R.; Xiang, M.; Frank, D. A. Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer Mol. Cell. Endocrinol. 2014, 382, 616-21
15. Muller, J.; Schust, J.; Berg, T. A high-throughput assay for signal transducer and activator of transcription 5b based on fluorescence polarization Anal. Biochem. 2008, 375, 249-54
16. Page, B. D.; Khoury, H.; Laister, R. C.; Fletcher, S.; Vellozo, M.; Manzoli, A.; Yue, P.; Turkson, J.; Minden, M. D.; Gunning, P. T. Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity J. Med. Chem. 2012, 55, 1047-55
17. Andricopulo, A. D.; Salum, L. B.; Abraham, D. J. Structure-based drug design strategies in medicinal chemistry Curr. Top. Med. Chem. 2009, 9, 771-90
18. Kraskouskaya, D.; Duodu, E.; Arpin, C. C.; Gunning, P. T. Progress towards the development of SH2 domain inhibitors Chem. Soc. Rev. 2013, 42, 3337-70
19. Liu, B. A.; Engelmann, B. W.; Nash, P. D. The language of SH2 domain interactions defines phosphotyrosine-mediated signal transduction FEBS Lett. 2012, 586, 2597-2605
20. Morris, G. M.; Goodsell, D. S.; Halliday, R.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a lamarckian genetic algorithm and empirical binding free energy function J. Comput. Chem. 1998, 19, 1639-62
21. Ren, Z.; Mao, X.; Mertens, C.; Krishnaraj, R.; Qin, J.; Mandal, P. K.; Romanowski, M. J.; McMurray, J. S.; Chen, X. Crystal structure of unphosphorylated stat3 core fragment Biochem. Biophy. Res. Commun. 2008, 374, 1-5
22. Park, I.; Chenglong, L. Characterization of molecular recognition of STAT3 SH2 domain inhibitors through molecular simulation J. Mol. Recognit. 2011, 24, 254-65